Security
Alpha Healthcare Acquisition Corp. Unit · AHACU
AHACUNASDAQUnitHistorical · closed Aug 26, 2021CIK 1818382Updated Oct 8, 2026
Name history
Alpha Healthcare Acquisition Corp. · through Aug 26, 2021
Current security for this SEC filerHUMA · NASDAQ
AHACU price & chart
Historical security
This listing closed Aug 26, 2021. Live provider charts are shown only for current listings.
Current security: HUMA
About the company
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extre…
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 116,366,000Source | 137,872,000Source | 128,223,000Source | 204,302,000Source |
| Property, Plant and Equipment, NetUSD | 18,544,000Source | 23,063,000Source | 26,791,000Source | 30,039,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 50,497,000Source | 44,937,000Source | 80,448,000Source | 149,772,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 441,000Source | — | 0Source | 31,000Source |
| Inventory, NetUSD | 13,589,000Source | — | — | — |
| Assets, CurrentUSD | 67,795,000Source | 47,859,000Source | 83,278,000Source | 154,208,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,268,000Source | 2,922,000Source | 2,830,000Source | 2,298,000Source |
| Operating Lease, Right-of-Use AssetUSD | 0Source | 600,000Source | 600,000Source | 682,000Source |
| Other Assets, NoncurrentUSD | 672,000Source | 1,251,000Source | 841,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 113,257,000Source | 190,541,000Source | 114,677,000Source | 87,374,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 20,000Source | 13,000Source | 10,000Source | 10,000Source |
| Additional Paid in CapitalUSD | 729,937,000Source | 633,333,000Source | 550,850,000Source | 543,456,000Source |
| Retained Earnings (Accumulated Deficit)USD | -726,848,000Source | -686,015,000Source | -537,314,000Source | -426,538,000Source |
| Stockholders' Equity Attributable to ParentUSD | 3,109,000Source | -52,669,000Source | 13,546,000Source | 116,928,000Source |
| Liabilities and EquityUSD | 116,366,000Source | 137,872,000Source | 128,223,000Source | 204,302,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 18,372,000Source | 19,954,000Source | 18,443,000Source | 19,580,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | 53,000Source | 50,000Source |
| Accounts Payable, CurrentUSD | 5,404,000Source | 4,490,000Source | 6,490,000Source | 1,595,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 500,000Source | 600,000Source | 632,000Source |
| Deferred Income Tax Liabilities, NetUSD | 762,000Source | 1,163,000Source | 1,518,000Source | 1,857,000Source |
| Other Liabilities, NoncurrentUSD | 1,583,000Source | 983,000Source | 789,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 10,540,000Source | 11,424,000Source | 9,340,000Source | 7,108,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 80,400,000Source | 151,900,000Source |
| Long-term DebtUSD | 35,444,000Source | — | — | — |
| Short-term InvestmentsUSD | — | — | 0Source | 2,107,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 9,753,000Source | 6,137,000Source | 6,828,000Source | 6,184,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 261,000Source | 0Source | -31,000Source | -145,000Source |
| Increase (Decrease) in InventoriesUSD | 21,827,000Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | 973,000Source | -1,962,000Source | 4,811,000Source | -509,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -105,042,000Source | -98,122,000Source | -73,305,000Source | -71,129,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -884,000Source | -1,572,000Source | -173,000Source | 4,845,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 884,000Source | 1,572,000Source | 2,280,000Source | 1,048,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 61,486,000Source | 114,183,000Source | 4,507,000Source | -1,446,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -44,440,000Source | 14,489,000Source | -68,971,000Source | -67,730,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 50,850,000Source | 95,290,000Source | 80,801,000Source | 149,772,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 0Source | 1,613,000Source | 2,668,000Source |
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 10,411,000Source | 6,137,000Source | 6,828,000Source | 6,184,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 80,400,000Source | 151,900,000Source |
| DepreciationUSD | 5,328,000Source | 5,104,000Source | 5,659,000Source | 6,151,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -5,000Source | -4,000Source | -18,000Source | -6,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | -22,267,000Source | 0Source | -2,421,000Source | 0Source |
| General and Administrative ExpenseUSD | 31,171,000Source | 25,799,000Source | 23,497,000Source | 22,883,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 11,250,000Source | 9,277,000Source | — | — |
| Investment Income, InterestUSD | 2,587,000Source | 4,104,000Source | 5,467,000Source | 2,629,000Source |
| Net Income (Loss) Attributable to ParentUSD | -40,833,000Source | -148,701,000Source | -110,776,000Source | -11,965,000Source |
| Nonoperating Income (Expense)USD | 67,304,000Source | -34,303,000Source | -10,729,000Source | 72,613,000Source |
| Operating ExpensesUSD | — | 114,398,000Source | 100,047,000Source | 86,143,000Source |
| Proceeds from Stock Options ExercisedUSD | 61,000Source | 1,511,000Source | 566,000Source | 535,000Source |
| Unrealized Gain (Loss) on DerivativesUSD | 38,765,000Source | 3,915,000Source | -260,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 2,038,000Source | — | — | — |
| Cost of RevenueUSD | 9,702,000Source | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Operating Income (Loss)USD | -108,137,000Source | -114,398,000Source | -100,047,000Source | -84,578,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -40,834,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -40,833,000Source | -148,701,000Source | -110,776,000Source | -11,965,000Source |
| Earnings Per Share, BasicUSD per share | -0.26Source | -1.26Source | -1.07Source | -0.12Source |
| Earnings Per Share, DilutedUSD per share | -0.26Source | -1.26Source | -1.07Source | -0.12Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 158,160,468Source | 118,479,097Source | 103,420,238Source | 103,051,366Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 158,160,468Source | 118,479,097Source | 103,420,238Source | 103,051,366Source |
| Interest Expense (non-operating)USD | 11,250,000Source | 9,277,000Source | — | — |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 110,175,000Source | — | — | — |
| General and Administrative ExpenseUSD | 31,171,000Source | 25,799,000Source | 23,497,000Source | 22,883,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -40,833,000Source | — | — | — |
| Interest ExpenseUSD | — | — | 6,599,000Source | 6,200,000Source |
| Investment Income, InterestUSD | 2,587,000Source | 4,104,000Source | 5,467,000Source | 2,629,000Source |
| Nonoperating Income (Expense)USD | 67,304,000Source | -34,303,000Source | -10,729,000Source | 72,613,000Source |
| Operating ExpensesUSD | — | 114,398,000Source | 100,047,000Source | 86,143,000Source |
| Research and Development ExpenseUSD | 69,302,000Source | 88,599,000Source | 76,550,000Source | 63,260,000Source |
Filing attachments
huma-ex99_1.htm · 8-K · 2026-09-28
Exhibit 99.1 Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) - Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company’s Board of Directors, both of whom bring substantial experience in the areas of co…
Read attachment ↗huma-ex4_1.htm · 10-Q · 2026-08-12
Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTION 4(a) AND SECTION 5(c) BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. COMMON STOCK PURCHASE WARRANT HUMACYTE, INC. Warrant Shares: 240,000 Issue …
Read attachment ↗tm2622949d1_ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 tm2622949d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update - Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug Administration (FDA) during the second half of 2026 - - FDA accepted IND for first-in-human clinical study of CTEV for CABG with P…
Read attachment ↗p15000772_ex99-1.htm · SCHEDULE 13G · 2026-06-22
EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the compl…
Read attachment ↗tm2617224d2_ex99-1.htm · 8-K · 2026-06-11
EX-99.1 4 tm2617224d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Humacyte, Inc. Announces Proposed Public Offering of Common Stock DURHAM, N.C., June 10, 2026 - Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has commenced an underwritten public offering of its common stock. In addition, Humacyte intends to grant the underwriters an option for a period of …
Read attachment ↗tm2617224d2_ex99-2.htm · 8-K · 2026-06-11
EX-99.2 5 tm2617224d2_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Humacyte, Inc. Announces Pricing of Public Offering of Common Stock DURHAM, N.C., June 10, 2026 - Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross …
Read attachment ↗